Status:
COMPLETED
Action of Epigenetic Modifiers in Cystic Fibrosis Treatment
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Cystic Fibrosis
Healthy Subjects
Eligibility:
All Genders
12+ years
Phase:
NA
Brief Summary
Epigenetic modifiers has been showed to rescue F508del-CFTR channel to apical membrane of epithelial cell lines. In this study, the investigators evaluate epigenetic modifiers effects firstly on CFTR ...
Eligibility Criteria
Inclusion
- General inclusion criteria :
- informed consent
- benefit from disease insurance regimen
- men and women
- Inclusion Criteria for CF patients
- 2 severe CF mutations
- age superior or equal to 12
- Inclusion Criteria for controls :
- age superior or equal to 18
- no smoker (for 5 years)
- General exclusion criteria :
- participation to an other interventionnal study
- subject in exclusion period
- law protected subject
- pregnant and breast fooding
- Specific Exclusion Criteria:
- Xylocaine hypersensibility
- Porphyria
- severe hepatic failure
- Epilepsy
- Severe cardiac failure
- local anesthesic contra indication
- Specific Control subject Exclusion Criteria:
- respiratory disease
- cystic fibrosis
- acute infection \< 6 weeks
- on treatment
- antibiotic treatment \< 3 months
Exclusion
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT01883284
Start Date
January 1 2012
End Date
November 1 2014
Last Update
December 3 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Respiratory Diseases Department
Montpellier, France, 34295